Clinical usefulness of CT in the treatment of stage I endometrial carcinoma

Alfredo La Fianza, Enrico Maria Di Maggio, Lorenzo Preda, Davide Coscia, Saverio Tateo, Rodolfo Campani

Research output: Contribution to journalArticlepeer-review


This retrospective study was aimed at assessing Computed Tomography (CT) capabilities in identifying low-and high-risk groups of clinical stage I endometrial carcinoma patients. CT of the pelvis was performed on 125 endometrial carcinoma patients who were divided into two groups based on T (stage and depth of myometrial invasion) and N (lymph node status) parameters. All patients had histologic evidence of well/moderately-differentiated adenocarcinoma (G1-G2) The low-risk group consisted of stage I patients with superficial myometrial involvement and no lymphadenopathy, while the high-risk group consisted of the patients with deep myometrial invasion and/or stage II and/or positive lymph nodes. All patients were operated on -i.e., total abdominal hysterectomy with vaginal cuff, bilateral salpingo-oophorectomy and pelvic lymphadenectomy. The patients were followed-up for 36 months at least. On the basis of CT findings, 85 patients were included in the low-risk group, but 11 misstaged cases were found at surgery in which lymphadenectomy never changed the factor risk. Only four relapses (4.7%) were observed in this group. Forty patients were included in the high-risk group: CT misstaged 20 cases and 12 relapses (30%) were observed. This study demonstrates the clinical value of CT in the assessment of radiologic risk factors in stage I endometrial carcinoma; CT findings can be used as guidelines for different treatments.

Original languageEnglish
Pages (from-to)567-571
Number of pages5
JournalRadiologia Medica
Issue number5
Publication statusPublished - May 1997


  • Endometrial cancer, CT
  • Endometrium, cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Clinical usefulness of CT in the treatment of stage I endometrial carcinoma'. Together they form a unique fingerprint.

Cite this